



WORKING GROUP MEETING MINUTES: Allergy Working Group

16th March 2023
REG Summit Lisbon

Meeting details																	
Meeting location	Lisbon Marriott Hotel, Lisbon / MS Teams																
Meeting date	Thursday 16 th March 2023																
Meeting time	14.00-15.00 local time																
Chair(s)	Désirée Larenas-Linnemann																
Attendees	<table><tbody><tr><td>Jerome Afochu</td><td>Thérese Lapperre</td></tr><tr><td>Randall Brown</td><td>Eva Nieto</td></tr><tr><td>Kristina Dowensee</td><td>Nikos Popadopolous</td></tr><tr><td>Monica Ruiz Garcia</td><td>Dermot Ryan</td></tr><tr><td>Aida Gomez</td><td>Guilherme Safioti</td></tr><tr><td>Xavier Jaumont</td><td>Angelika Sager</td></tr><tr><td>Désirée Larenas-Linnemann</td><td>Glenis Scadding</td></tr><tr><td>Graham Lough</td><td></td></tr></tbody></table>	Jerome Afochu	Thérese Lapperre	Randall Brown	Eva Nieto	Kristina Dowensee	Nikos Popadopolous	Monica Ruiz Garcia	Dermot Ryan	Aida Gomez	Guilherme Safioti	Xavier Jaumont	Angelika Sager	Désirée Larenas-Linnemann	Glenis Scadding	Graham Lough	
Jerome Afochu	Thérese Lapperre																
Randall Brown	Eva Nieto																
Kristina Dowensee	Nikos Popadopolous																
Monica Ruiz Garcia	Dermot Ryan																
Aida Gomez	Guilherme Safioti																
Xavier Jaumont	Angelika Sager																
Désirée Larenas-Linnemann	Glenis Scadding																
Graham Lough																	
Objectives																	
1	New project possibilities																

Items	
New project possibilities	<p>The group discussed a potential project: "Prospective, observational, multinational study on the effectiveness of AIT in moderate allergic asthma"</p> <ul style="list-style-type: none">• <u>Challenge</u>: Exacerbation is the primary outcome, but rare event.<ul style="list-style-type: none">○ Which to assess? Hospitalizations? Emergency room visits?○ Suggested also time off work/school○ Suggested also annualized exacerbation rate (not no. of exacerbations)○ Suggested maybe exacerbation is a secondary outcome• <u>Challenge</u>: search for the balance between how to minimize the effort/time required to participate by physician / patient and capture the maximum of data possible.• <u>Challenge</u>: criteria for how symptomatic patients are. e-DASTHMA is an interesting tool. Reimbursement criteria vary by country.



	<ul style="list-style-type: none">• <u>Challenge</u>: Definition of moderate asthma: must go beyond 'those who are on ICS-LABA' as this is nowadays not only prescribed in GINA Step 3/4.<ul style="list-style-type: none">○ Must exclude severe and differentiate between mild and moderate.○ Including spirometry would be much recommended○ Include quality of life○ Disease uncontrolled on just a steroid dose? Medium dose?<ul style="list-style-type: none">▪ Need a threshold, e.g., certain VAS score for period of time before starting• Need to capture upper airways symptoms – VAS nasal/eye symptoms• <u>Challenge</u> – availability differs country to country e.g., spirometry• <u>Challenge</u> – If study is not a registry (instead a prospective trial), then what is a suitable control?<ul style="list-style-type: none">○ Suggested patient self-controlled case series (i.e., patients used as on control pre- / post-AIT)
Action Points	<ul style="list-style-type: none">• A new draft of a research proposal will be developed and send to a project steering committee for refinement and further discussion.